Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for Kiniksa Pharmaceuticals International (KNSA) over the last 6 years, with Dec 2024 value amounting to -$0.60.

  • Kiniksa Pharmaceuticals International's EPS (Weighted Average and Diluted) rose 227.78% to $0.23 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.45, marking a year-over-year increase of 446.15%. This contributed to the annual value of -$0.60 for FY2024, which is 400.00% down from last year.
  • As of FY2024, Kiniksa Pharmaceuticals International's EPS (Weighted Average and Diluted) stood at -$0.60, which was down 400.00% from $0.20 recorded in FY2023.
  • Kiniksa Pharmaceuticals International's 5-year EPS (Weighted Average and Diluted) high stood at $2.60 for FY2022, and its period low was -$2.61 during FY2020.
  • Its 3-year average for EPS (Weighted Average and Diluted) is $0.73, with a median of $0.20 in 2023.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's EPS (Weighted Average and Diluted) soared by 213.04% in 2022, and later slumped by 400.00% in 2024.
  • Yearly analysis of 5 years shows Kiniksa Pharmaceuticals International's EPS (Weighted Average and Diluted) stood at -$2.61 in 2020, then rose by 11.88% to -$2.30 in 2021, then spiked by 213.04% to $2.60 in 2022, then plummeted by 92.31% to $0.20 in 2023, then plummeted by 400.00% to -$0.60 in 2024.